How AstraZeneca’s $400B Bristol Myers deal fell apart
AstraZeneca’s board scrapped merger talks with Bristol Myers Squibb on Aug. 3, days after reports emerged that the companies were discussing a roughly $400 billion tie-up, according to an Aug. 11 report from the Financial Times. The two companies had been in serious talks throughout the spring and summer and were nearing agreement on price, […] The post How AstraZeneca’s $400B Bristol Myers deal fell apart appeared first on Becker's Hospital Review | Healthcare News &...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.